Interested? Contact Us
SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO
Vir Biotechnology priced its initial public offering (IPO) at $20 a share on Thursday, at the bottom end of expectations, a fresh blow for SoftBank Group Corp's Vision Fund, owner of 21% in the infectious disease researcher.
Stay Informed
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.
